EGCG as a safe, preventive approach to reduce liver cancer risk in cirrhosis
Official title: Epigallocatechin gallate for prevention of lethal cirrhosis complications
Funded at Ut Southwestern Medical Center · NIH-11179209 · Data updated 2026-11-12
Aiming to see if a green tea compound (EGCG) can safely lower the chance of liver cancer developing in people with cirrhosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | September 6, 2023 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $480,346 |
| NIH project number | 5R01CA282178-03 |
| Project ID | NIH-11179209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cirrhosis who are at high risk for hepatocellular carcinoma.
✕Less likely to help
Patients without cirrhosis or those unable to tolerate EGCG may not benefit from this approach.
What this research studies
This grant explores whether EGCG can safely dampen signals that predict liver cancer risk in patients with cirrhosis. Researchers will monitor safety and biomarkers in participants and use a liver tissue model to understand how EGCG affects cancer-related pathways. The study builds on prior lab and organ tissue work and uses a patient-centered approach to translate findings into potential chemoprevention for cirrhosis. If successful, it could lead to a new strategy to reduce liver cancer risk in a high-risk population.
Why it matters
Potential benefit: If successful, patients with cirrhosis may have a reduced risk of developing hepatocellular carcinoma.
How similar studies have gone: Prior lab and tissue studies support the potential, but human data are needed to confirm safety and effect in patients.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Hoshida, Yujin — Ut Southwestern Medical Center
- Study coordinator: Hoshida, Yujin
Related research
Other NIH-funded projects on the same topics.
-
Statin therapy for people with compensated cirrhosis
A big, long-term study at a major university is looking at whether statins can help people with compensated cirrhosis live longer and feel better.
-
Liver Cirrhosis Network: Centers for Clinical Research
A multicenter study in people with cirrhosis from different causes (including HIV, NASH, and alcohol-related liver disease) to collect data and samples and test new ways to predict and monitor disease progression.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
-
Liver Cirrhosis Network: Mayo Clinic's Clinical Research Center
A Mayo Clinic-led project will follow and help people with compensated cirrhosis, using data, imaging, and a big AI tool to predict when complications may happen and test whether a statin can improve outcomes.
-
Understanding how risk factors affect progression of cirrhosis and response to statins in patients with cirrhosis
This project follows people with cirrhosis to see what factors speed up their liver disease and whether statin medicines help prevent worsening.
-
Cirrhosis Network study to understand mortality and therapies
A large, multi-center study in people with cirrhosis to find better ways to predict deaths and test the potential of statins to prevent complications like liver cancer and liver failure.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.